**
The ongoing conflict in Iran has triggered significant disruptions in the supply of essential medications across the UK, leaving many epilepsy patients grappling with potentially life-threatening consequences. As the war escalates, the availability of crucial drugs, including those for epilepsy, has diminished sharply, prompting urgent calls from health charities for the government to bolster supply chain resilience.
Crisis in Medication Supply
An estimated 630,000 individuals in the UK live with epilepsy, relying on prescribed medications to manage their condition and prevent seizures. Unfortunately, recent reports indicate that many patients are being forced to skip doses due to widespread shortages. Beth Baker-Carey, a 28-year-old from Doncaster, articulates the anxiety that accompanies this situation: “It’s really scary to think that through no fault of my own, this could be the reason I don’t wake up in the morning.” Having battled seizures since childhood, she is acutely aware of the dangers posed by inconsistent medication intake.
Pharmacies have increasingly reported stock shortages, a situation exacerbated by the ongoing conflict in the Strait of Hormuz. Since the war began in February, Baker-Carey has faced daunting challenges in securing her medication, often having to visit multiple pharmacies only to find them out of stock. “I’ve had to jump through hoops… sometimes late at night, and I’ve been told to just skip it, which is not really wise for a person with epilepsy,” she explains.
The Ripple Effect of Supply Chain Disruptions
Experts in the field emphasise the critical importance of maintaining a consistent medication regimen for epilepsy patients. Pharmacist Thorrun Govind highlights the clinical risks associated with disrupted access to anti-seizure medications. “Disruption can understandably cause concern and, in some cases, clinical risk,” she warns. This sentiment is echoed by Chloe Christoforou, a 29-year-old patient from North London, who has experienced a noticeable decline in her stability due to the stress of accessing her medicines. After years of managing her condition effectively, she now faces an alarming increase in seizure frequency, from three per week to three per day.
Christoforou’s struggles reflect a broader trend, as she has been forced to travel outside of London to obtain her medication. She recounts a harrowing reality: “I go to pick up my prescription for 56 tablets a month, but I get about 12. That lasts me maybe two to three days.” This precarious situation has led her to fear the potential for sudden death, a rare but tragic outcome known as Sudden Unexpected Death in Epilepsy (SUDEP).
Economic Factors Compounding the Crisis
The rising costs of medicines are a significant factor contributing to the current shortages. The pharmaceutical industry is grappling with surging global prices, which can lead to pharmacies dispensing medications at a loss. As a result, it becomes increasingly challenging for these establishments to maintain adequate stock levels. According to Medicines UK, if the geopolitical tensions between the US and Iran persist, shortages could extend beyond epilepsy medications to include paracetamol, antibiotics, and even cancer treatments.
Dr Leyla Hannbeck, chief executive of the Independent Pharmacies Association, points out that many pharmaceuticals depend on petroleum-derived inputs, which are vulnerable to disruptions in supply chains. “We are increasingly concerned that the disruption in the Strait of Hormuz is worsening medicines shortages in the UK,” she states. “In recent months, we have already seen a record rise in the price pharmacies have to pay to source prescription-only medicines, leaving many struggling to afford supply and often dispensing at a loss.”
Advocacy for Change
In response to these alarming developments, the Epilepsy Society has called upon the UK government to take decisive action to safeguard the supply chains for essential medications. Chief executive Clare Pelham has underscored the precarious nature of epilepsy, referring to it as a “cliff-edge condition,” where missing even a single dose can have fatal consequences. “We are calling on the government to protect people with cliff-edge conditions and to ensure their essential medicine supply chains are robust and water-tight,” Pelham insists.
The Department of Health and Social Care has been approached for comments regarding the ongoing crisis, but as patients continue to face uncertainty, the need for immediate government intervention has never been more pressing.
Why it Matters
The current medicine shortages pose a severe risk not only to the health of epilepsy patients but also to the wider public health landscape. With the potential for increased hospital admissions and a rise in preventable deaths, the implications of these supply chain issues extend far beyond individual experiences. For the government and public health officials, ensuring the reliability of medication supplies must become a top priority, particularly in light of the vulnerabilities exposed by geopolitical tensions. The lives of countless individuals hang in the balance, underscoring the urgent necessity for a robust response to this escalating crisis.
